AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Viking Therapeutics Plunges 37.82% Despite Positive Rival News
Generated by AI AgentAinvest Pre-Market Radar
Tuesday, Aug 19, 2025 7:38 am ET1min read
Aime SummaryOn August 19, 2025,
experienced a significant drop of 37.82% in pre-market trading, marking a notable decline in its stock performance.Viking Therapeutics' recent stock performance was influenced by several key factors. Positive news from a rival company,
, sparked a sympathy rally for Novo Nordisk's obesity drug, Wegovy, received FDA approval for a new indication, noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), which boosted investor sentiment towards obesity drug developers, including Viking Therapeutics.Additionally, a positive research note from Piper Sandler's analyst Biren Amin further improved sentiment. Amin reiterated his overweight recommendation and $71-per-share price target for Viking Therapeutics, citing the prospects for the company's investigational weight-loss drug, VK2735. The phase 3 study readout for the oral version of VK2735 is expected within the current calendar quarter, with potential sales of $2.1 billion if successful.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Esperion Therapeutics shares plunge 5.14% on Dec. 31 2025 due to regulatory and pipeline shifts
Dec.31 2025
Ses AI (NYSE: SES) plunges 6.28% as investors unwind holiday-driven rally gains amid mixed corporate signals.
Dec.31 2025
Novabay Pharmaceuticals Inc (NBY) Surges 27.57% in Pre-Market on December 31 as Small-Cap Biopharma Gains Lead
Dec.31 2025
Dingdong (Cayman) shares plunge 7.09% amid mixed earnings and strategic shifts
Dec.31 2025
Flushing Financial Corp. Plunges 8.94% Amid Renewed Merger Scrutiny
Dec.31 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet